191 related articles for article (PubMed ID: 32684241)
1. Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Hwang S; Kim S; Kim K; Yeom J; Park S; Kim I
BMB Rep; 2020 Nov; 53(11):576-581. PubMed ID: 32684241
[TBL] [Abstract][Full Text] [Related]
2. BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
Kim Y; Kim YS; Kim DE; Lee JS; Song JH; Kim HG; Cho DH; Jeong SY; Jin DH; Jang SJ; Seol HS; Suh YA; Lee SJ; Kim CS; Koh JY; Hwang JJ
Autophagy; 2013 Dec; 9(12):2126-39. PubMed ID: 24322755
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
4. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
5. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo.
Park KE; Johnson CM; Cabot RA
Reprod Fertil Dev; 2012; 24(6):813-21. PubMed ID: 22781932
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.
Cho HS; Kelly JD; Hayami S; Toyokawa G; Takawa M; Yoshimatsu M; Tsunoda T; Field HI; Neal DE; Ponder BA; Nakamura Y; Hamamoto R
Neoplasia; 2011 Aug; 13(8):676-84. PubMed ID: 21847359
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.
Park SE; Yi HJ; Suh N; Park YY; Koh JY; Jeong SY; Cho DH; Kim CS; Hwang JJ
Oncotarget; 2016 Jun; 7(26):39796-39808. PubMed ID: 27174920
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
9. LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylating H3K9 in the CDH1 promoter region via the recruitment of the EHMT2/SNAI1 complex.
Song W; Gu Y; Lu S; Wu H; Cheng Z; Hu J; Qian Y; Zheng Y; Fan H
Cell Prolif; 2019 Jul; 52(4):e12621. PubMed ID: 31012192
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL.
Namgung Y; Kim SY; Kim I
Anticancer Res; 2019 Jul; 39(7):3571-3578. PubMed ID: 31262881
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Chen G; Yu X; Zhang M; Zheng A; Wang Z; Zuo Y; Liang Q; Jiang D; Chen Y; Zhao L; Jiang L; Li D; Liao S
Cytogenet Genome Res; 2019; 158(4):205-212. PubMed ID: 31434093
[TBL] [Abstract][Full Text] [Related]
12. Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency.
Nguyen K; Das B; Dobrowolski C; Karn J
mBio; 2017 Feb; 8(1):. PubMed ID: 28246360
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.
Loh SW; Ng WL; Yeo KS; Lim YY; Ea CK
PLoS One; 2014; 9(7):e103915. PubMed ID: 25079219
[TBL] [Abstract][Full Text] [Related]
14. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
15. EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Kim H; Choi SY; Lim J; Lindroth AM; Park YJ
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028644
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Singh N; Ramĩrez-Carvajal L; de Los Santos T; Golding MC; Long CR
J Interferon Cytokine Res; 2016 Jan; 36(1):37-47. PubMed ID: 26418342
[TBL] [Abstract][Full Text] [Related]
17. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.
Renneville A; Van Galen P; Canver MC; McConkey M; Krill-Burger JM; Dorfman DM; Holson EB; Bernstein BE; Orkin SH; Bauer DE; Ebert BL
Blood; 2015 Oct; 126(16):1930-9. PubMed ID: 26320100
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
Wojtala M; Macierzyńska-Piotrowska E; Rybaczek D; Pirola L; Balcerczyk A
Pharmacol Res; 2018 Feb; 128():252-263. PubMed ID: 29113759
[TBL] [Abstract][Full Text] [Related]
19. The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.
Fan JD; Lei PJ; Zheng JY; Wang X; Li S; Liu H; He YL; Wang ZN; Wei G; Zhang X; Li LY; Wu M
PLoS One; 2015; 10(1):e0116782. PubMed ID: 25562686
[TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
